Global Hepatitis C Virus (HCV) Market - An Analysis
Hepatitis C virus (HCV) is commonly spread through blood from a person who has been infected through use of shared needles or equipment used to inject drugs. HCV is a liver-infecting virus that causes acute (new and short-lived) and chronic (long-lasting) forms of hepatitis C.
The incidence rates of HCV vary noticeably, registering the highest rate in the North America. In the past few years, the cases of HCV have increased tremendously in the US, European, Asian and African regions. Comprising of two segments - diagnostic and treatment, the HCV market is driven by various factors like growing world population, obesity, increasing number of HCV incidences globally and rise in number of HCV positive drug addicts.
The global market for HCV drugs represents an area of potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technologies, large number of companies are focused on developing innovative HCV drugs. Further, the companies are forming alliances and agreements to develop effective treatments for HCV. In the long-term, the growth of global HCV drugs market is expected to come more from emerging markets like the Asia-Pacific, Middle East countries, African and Latin America countries as these regions are likely to register maximum number of HCV incidences in years to come due to increase in number of HCV positive drug addicts.
This report titled “Global Hepatitis C Virus (HCV) Market– An Analysis” analyzes the various types, stages and incidences of HCV in different geographies. In the report, the markets for diagnosis and treatment of hepatitis C virus, including overall HCV drugs market, have been analyzed. The report also discusses the various factors that will drive the HCV diagnosis and treatment market. Key HCV market trends and issues have also been discussed. The report also presents the competitive structure of the industry and profiles major players in the HCV drugs market including Roche, Merck Pharmaceutical and Vertex Pharmaceutical.
Further, we have predicted the future growth of the global HCV drugs market by combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings. We employed various significant variables that have an impact on this industry and created regression models with SPSS to determine the future direction of the industry.
The incidence rates of HCV vary noticeably, registering the highest rate in the North America. In the past few years, the cases of HCV have increased tremendously in the US, European, Asian and African regions. Comprising of two segments - diagnostic and treatment, the HCV market is driven by various factors like growing world population, obesity, increasing number of HCV incidences globally and rise in number of HCV positive drug addicts.
The global market for HCV drugs represents an area of potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technologies, large number of companies are focused on developing innovative HCV drugs. Further, the companies are forming alliances and agreements to develop effective treatments for HCV. In the long-term, the growth of global HCV drugs market is expected to come more from emerging markets like the Asia-Pacific, Middle East countries, African and Latin America countries as these regions are likely to register maximum number of HCV incidences in years to come due to increase in number of HCV positive drug addicts.
This report titled “Global Hepatitis C Virus (HCV) Market– An Analysis” analyzes the various types, stages and incidences of HCV in different geographies. In the report, the markets for diagnosis and treatment of hepatitis C virus, including overall HCV drugs market, have been analyzed. The report also discusses the various factors that will drive the HCV diagnosis and treatment market. Key HCV market trends and issues have also been discussed. The report also presents the competitive structure of the industry and profiles major players in the HCV drugs market including Roche, Merck Pharmaceutical and Vertex Pharmaceutical.
Further, we have predicted the future growth of the global HCV drugs market by combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings. We employed various significant variables that have an impact on this industry and created regression models with SPSS to determine the future direction of the industry.
1. HEPATITIS C VIRUS (HCV) MARKET OVERVIEW
1.1 HCV Market: Introduction
1.2 HCV Market Size
1.2.1 Global HCV Market
2. REGIONAL ANALYSIS
2.1 North America
2.2 Western Europe
2.3 North Africa & Middle East
2.4 Eastern Europe & Central Europe
2.5 Sub & Sahara African Region
2.6 South & South East Asia
2.7 East Asia & Pacific
2.8 Australia & New Zealand
2.9 Latin America & Caribbean
3. HEPATITIS C VIRUS (HCV): DIAGNOSIS MARKET
3.1 Hepatitis C Virus Diagnosis: Introduction
3.2 Hepatitis C Virus Diagnosis: Market Size
4. HEPATITIS C VIRUS (HCV): TREATMENT MARKET
4.1 Hepatitis C Virus (HCV) Treatment Market: Introduction
4.2 Hepatitis C Virus (HCV) Treatment: Market Size
4.3 Hepatitis C Virus (HCV) Drugs Market
5. MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Growing Worldwide Population
5.1.2 Rise in number of drug addicts
5.2 Key Issues
5.2.1 Lesser percentage of survival in obese and diabetic HCV patients
5.2.2 Rising HCV treatment Cost
5.2.3 Lesser availability of insurers in HCV
5.3 Market Trends
5.3.1 Advancement in new drugs
5.3.2 Paradigm shift to HCV herbal supplement
6. COMPETITIVE LANDSCAPE
6.1 Roche Pharmaceutical
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Merck Pharmaceutical
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Vertex Pharmaceutical
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
7. MARKET OUTLOOK
7.1 Market Forecast
7.2 Forecast Methodology
7.2.1 Dependent and Independent Variables
7.2.2 Correlation Analysis
7.2.3 Regression Analysis
1.1 HCV Market: Introduction
1.2 HCV Market Size
1.2.1 Global HCV Market
2. REGIONAL ANALYSIS
2.1 North America
2.2 Western Europe
2.3 North Africa & Middle East
2.4 Eastern Europe & Central Europe
2.5 Sub & Sahara African Region
2.6 South & South East Asia
2.7 East Asia & Pacific
2.8 Australia & New Zealand
2.9 Latin America & Caribbean
3. HEPATITIS C VIRUS (HCV): DIAGNOSIS MARKET
3.1 Hepatitis C Virus Diagnosis: Introduction
3.2 Hepatitis C Virus Diagnosis: Market Size
4. HEPATITIS C VIRUS (HCV): TREATMENT MARKET
4.1 Hepatitis C Virus (HCV) Treatment Market: Introduction
4.2 Hepatitis C Virus (HCV) Treatment: Market Size
4.3 Hepatitis C Virus (HCV) Drugs Market
5. MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Growing Worldwide Population
5.1.2 Rise in number of drug addicts
5.2 Key Issues
5.2.1 Lesser percentage of survival in obese and diabetic HCV patients
5.2.2 Rising HCV treatment Cost
5.2.3 Lesser availability of insurers in HCV
5.3 Market Trends
5.3.1 Advancement in new drugs
5.3.2 Paradigm shift to HCV herbal supplement
6. COMPETITIVE LANDSCAPE
6.1 Roche Pharmaceutical
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Merck Pharmaceutical
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Vertex Pharmaceutical
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
7. MARKET OUTLOOK
7.1 Market Forecast
7.2 Forecast Methodology
7.2.1 Dependent and Independent Variables
7.2.2 Correlation Analysis
7.2.3 Regression Analysis
LIST OF CHARTS & TABLES
Risk Factors for infection with Hepatitis C Virus
New HCV Cases Registered Globally, 2005-2010
HCV Infection Rate Reported in Male & Female Globally, 2005-2009
HCV Infection Rate Reported by Age-Group & Gender Globally, 2005-2009
HCV Infection Rate Reported by Age-Group among Females Globally, 2005-2009
HCV Infection Rate Reported by Age-Group among Males Globally, 2005-2009
Acute & Chronic HCV Infection Rate Registered Globally, 2005-2009
Percentage Breakup of New HCV Cases by Geography, 2010
New HCV Cases Registered in North America, 2005-2010
New HCV Cases Registered by Age Group in North America, 2010
New HCV Cases Registered in Western Europe, 2005-2010
Hepatitis C Virus infected by Race & Ethnicity in Western Europe, 2010
New HCV Cases Registered in North Africa & Middle East, 2005-2010
New HCV Cases Registered in Eastern & Central Europe, 2005-2010
New HCV Cases Registered in Sub & Sahara African Region, 2005-2010
New HCV Cases Registered in South & South East Asia, 2005-2010
New HCV Cases Registered in East Asia & Pacific, 2005-2010
New HCV Cases Registered in Australia & New Zealand, 2005-2010
New HCV Cases Registered in Latin America & Caribbean, 2005-2010
Percentage Detection of Anti-HCV antibodies in Patients
Patients Infected with HCV Genotypes Globally, 2010
HCV Patients Segmentation Globally, 2010
Number of HCV Patients Diagnosed Globally, 2008–2015F
Number of HCV Patients Diagnosed by Race Globally, 2009
Number of HCV Patients Diagnosed by Age Group Globally, 2010
Number of Patients Provided with Interferon (IFN) Therapy in the US, 2000-2010
PEG-Interferon (IFN)/Ribavirin Therapy Access to different Patient segments Globally, 2010
Number of HCV Patients Underwent Treatment Globally, 2007–2015F
Worldwide HCV Drugs Market Size by Value, 2006–2010
The US HCV Drugs Market Size by Value, 2009–2012F
Worldwide Population (2006-2013F)
Number of Drug Addicts Underwent HCV Treatment (2006-2013F)
Survival rates in HCV Patients Suffering from Diabetes and Obesity, 2010
HCV Treatment Cost, 2008-2010
Net Sales and Net Income Comparison (2008-2010)
Net Sales and Net Income Comparison (2008-2010)
Net Sales and Net Income Comparison (2008-2010)
Global HCV Drugs Market Forecast 2010-2014F
Response Rates of Treatment in Patients
Treatment Approach will Change Significantly until 2015
Worldwide Sales Estimates for Telaprevir & Boceprevir (US$ millions)
Dependent & Independent Variables (2006–2010)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output
Risk Factors for infection with Hepatitis C Virus
New HCV Cases Registered Globally, 2005-2010
HCV Infection Rate Reported in Male & Female Globally, 2005-2009
HCV Infection Rate Reported by Age-Group & Gender Globally, 2005-2009
HCV Infection Rate Reported by Age-Group among Females Globally, 2005-2009
HCV Infection Rate Reported by Age-Group among Males Globally, 2005-2009
Acute & Chronic HCV Infection Rate Registered Globally, 2005-2009
Percentage Breakup of New HCV Cases by Geography, 2010
New HCV Cases Registered in North America, 2005-2010
New HCV Cases Registered by Age Group in North America, 2010
New HCV Cases Registered in Western Europe, 2005-2010
Hepatitis C Virus infected by Race & Ethnicity in Western Europe, 2010
New HCV Cases Registered in North Africa & Middle East, 2005-2010
New HCV Cases Registered in Eastern & Central Europe, 2005-2010
New HCV Cases Registered in Sub & Sahara African Region, 2005-2010
New HCV Cases Registered in South & South East Asia, 2005-2010
New HCV Cases Registered in East Asia & Pacific, 2005-2010
New HCV Cases Registered in Australia & New Zealand, 2005-2010
New HCV Cases Registered in Latin America & Caribbean, 2005-2010
Percentage Detection of Anti-HCV antibodies in Patients
Patients Infected with HCV Genotypes Globally, 2010
HCV Patients Segmentation Globally, 2010
Number of HCV Patients Diagnosed Globally, 2008–2015F
Number of HCV Patients Diagnosed by Race Globally, 2009
Number of HCV Patients Diagnosed by Age Group Globally, 2010
Number of Patients Provided with Interferon (IFN) Therapy in the US, 2000-2010
PEG-Interferon (IFN)/Ribavirin Therapy Access to different Patient segments Globally, 2010
Number of HCV Patients Underwent Treatment Globally, 2007–2015F
Worldwide HCV Drugs Market Size by Value, 2006–2010
The US HCV Drugs Market Size by Value, 2009–2012F
Worldwide Population (2006-2013F)
Number of Drug Addicts Underwent HCV Treatment (2006-2013F)
Survival rates in HCV Patients Suffering from Diabetes and Obesity, 2010
HCV Treatment Cost, 2008-2010
Net Sales and Net Income Comparison (2008-2010)
Net Sales and Net Income Comparison (2008-2010)
Net Sales and Net Income Comparison (2008-2010)
Global HCV Drugs Market Forecast 2010-2014F
Response Rates of Treatment in Patients
Treatment Approach will Change Significantly until 2015
Worldwide Sales Estimates for Telaprevir & Boceprevir (US$ millions)
Dependent & Independent Variables (2006–2010)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output
